Ronald J. Buckanovich, MD, PhD, on Ovarian Cancer: Expert Perspective on the SOLO2 Trial

2017 ASCO Annual Meeting
Tweet this page

Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on health-related quality of life with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer. (Abstract 5507)

Advertisement

Advertisement



Advertisement